177 Lutetium PSMA 617 - Endocyte

Drug Profile

177 Lutetium PSMA 617 - Endocyte

Alternative Names: 177LU-PSMA-617 - Endocyte

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Endocyte
  • Developer Australian Nuclear Science and Technology Organisation
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Prostate cancer

Most Recent Events

  • 02 Oct 2017 Endocyte announces intention to file regulatory application to initiate a pivotal phase III trial in Prostate cancer in early 2018
  • 02 Oct 2017 Endocyte plans a pivotal phase III trial in Prostate cancer (Metastatic disease, Second-line therapy or greater) in the first half of 2018
  • 12 Sep 2017 Efficacy data from a phase I/II trial presented at the Annual Meeting of the European Society of Medical Oncology (ESMO-2017) .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top